Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,190 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 85% confidence The document is a statutory disclosure letter addressed to the NSE and BSE under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, specifically Regulation 31(4) concerning share encumbrances by the promoter group. It is a compliance/regulatory announcement rather than a financial report, board change, dividend notice, or proxy solicitation. This falls under the general “Regulatory Filings” category.
2026-05-27 English
Transcript of Earnings Call pertaining to audited financial results of the Company for the quarter and financial year ended March 31, 2026
Call Transcript Classification · 98% confidence The document begins with a formal letter to stock exchanges pursuant to SEBI Regulation 30, enclosing the full transcript of the company’s Q4 & FY26 earnings conference call. The body of the document then provides a complete, verbatim record of the earnings call dialogue (Moderator instructions, executive remarks, Q&A). This structure and content precisely match the definition of a Call Transcript (CT).
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 92% confidence The document is a letter to stock exchanges under SEBI regulations that encloses and publishes the full text of the Q4 FY26 earnings conference call transcript (including moderator introduction, management discussion, and Q&A). It contains the complete call dialogue rather than just a summary or key highlights. Therefore, it is a Call Transcript (CT).
2026-05-21 English
General Updates
Regulatory Filings Classification · 98% confidence The document is a brief disclosure letter under Regulation 30 of the SEBI Listing Regulations notifying the stock exchanges of the completion of a US-FDA cGMP inspection and issuance of Form 483 observations. It contains no financial statements or substantive financial data and is not announcing publication of a formal financial report. This fits the definition of a general regulatory announcement, classifying it as Regulatory Filings (RNS).
2026-05-20 English
Completion of US-FDA Inspection at the Company''s flagship facility in Bangalore
Regulatory Filings Classification · 85% confidence The document is a stock exchange disclosure under SEBI Listing Regulation 30 announcing the completion of a US FDA cGMP inspection and issuance of a Form 483. It is a regulatory update to stock exchanges rather than a financial report, earnings release, or management change. This fits the “Regulatory Filings” category.
2026-05-20 English
Update with regard to our intimation dated May 18, 2026
Board/Management Information Classification · 99% confidence The document is a formal stock exchange filing by Strides Pharma Science Limited disclosing changes in its Board of Directors, Key Managerial Personnel (KMP), and Senior Management Personnel (SMP) under SEBI Listing Regulations. It details appointments, re-designations, and updates to the company’s governance structure rather than presenting financial results or other report types. This aligns directly with the “Board/Management Information” category.
2026-05-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.